


Claims


1. A platelet increasing agent comprising a 2-acylaminothiazole derivative represented by formula (I) or a
5 pharmaceutically acceptable salt thereof as an active ingredient.



[Symbols in the formula have the following meanings.

A: a lower alkylene

10 R¹: a group represented by the formula (II), or cyclic amino which may be substituted.



[Symbols in the formula have the following meanings.

15 R¹¹: H, a lower alkyl which may be substituted, or a cycloalkyl which may be substituted. When A represents methylene, R¹¹ may be present as methylene which is bridged to thienyl or phenyl represented by R². When A represents methylene, R¹¹ may be present as a lower alkylene which may 20 be substituted and which forms a ring closed at the methylene represented by A.

R¹²: a lower alkyl, a cycloalkyl or a non-aromatic heterocycle, each of which may be substituted.]

R²: thienyl or phenyl, each of which may be substituted.

5 R³: an aromatic heterocycle, an aryl or cyclic amino, each of which may be substituted.]

2. The pharmaceutical composition according to claim 1, wherein A is methylene.

10


3. The pharmaceutical composition according to claim 2, wherein R² is thienyl or phenyl, each of which is substituted with one or more groups selected from the group consisting of a lower alkyl which may be substituted with 15 one or more halogens, and a halogen.

4. The pharmaceutical composition according to any of claims 1 to 3, which is a thrombocytopenia treating agent.

20

5. The pharmaceutical composition according to any of claims 1 to 3, which is a c-Mpl ligand.

25 6. A 2-acylaminothiazole derivative represented by the formula (III) or a pharmaceutically acceptable salt thereof.



[Symbols in the formula have the following meanings.

B: a group represented by A according to claim 1.

R^4 : a group represented by R^1 according to claim 1.

5 R^5 : a group represented by R^2 according to claim 1.

10 R^6 : a group represented by R^3 according to claim 1,
provided that unsubstituted phenyl and indole
which may be substituted are excluded.]

10 7. The compound according to claim 6, wherein B is
methylen.

15 8. The compound according to claim 7, wherein R^5 is
thienyl or phenyl, each of which is substituted with one or
more groups selected from the group consisting of a lower
alkyl which may be substituted with one or more halogens,
and a halogen.

20 9. The compound according to claim 8, wherein R^6 is
pyridyl which may be substituted, or phenyl which is
substituted.

10. The compound according to claim 9, wherein R^6 is
pyridin-3-yl whose 5-position is substituted with a group

selected from the group consisting of chloro and fluoro, and whose 6-position is substituted, or phenyl whose 3-position is substituted with a group selected from the group consisting of chloro and fluoro, whose 5-position is
5 substituted with a group selected from the member consisting of -H, chloro and fluoro, and whose 4-position is substituted.

11. Among the compounds according to claim 6,
10 1-{3-chloro-5-[(4-(4-chlorothiophen-2-yl)-5-
 { [cyclobutyl(methyl)amino]methyl}thiazol-2-yl)carbamoyl]-2-
 pyridyl)piperidine-4-carboxylic acid,
 1-(5-{ [5-{ (butyl(methyl)amino)methyl}-4-
 chlorothiophen-2-yl]thiazol-2-yl]carbamoyl}-3-chloro-2-
15 pyridyl)piperidine-4-carboxylic acid,
 1-{5-[(4-(4-chlorothiophen-2-yl)-5-{ [(2R)-2-
 methylpyrrolidin-1-yl]methyl}thiazol-2-yl)carbamoyl]-3-
 fluoro-2-pyridyl)piperidin-4-carboxylic acid,
 1-{3-chloro-5-[(4-(4-chlorothiophen-2-yl)-5-{ [(2S)-2-
20 methylpyrrolidin-1-yl]methyl}thiazol-2-yl)carbamoyl]-2-
 pyridyl)piperidine-4-carboxylic acid,
 1-(3-chloro-5-{ [4-(4-chlorothiophen-2-yl)-5-
 (dimethylaminomethyl)thiazol-2-yl]carbamoyl}-2-
 pyridyl)piperidine-4-carboxylic acid,

1-{3-chloro-5-[(4-(4-chlorothiophen-2-yl)-5-
{[isopropyl(methyl)amino]methyl}thiazol-2-yl)carbamoyl]-2-
pyridyl)piperidine-4-carboxylic acid,
4-[{3-chloro-5-[(4-(4-chlorothiophen-2-yl)-5-
5 {[isopropyl(methyl)amino]methyl}thiazol-2-yl)carbamoyl]-2-
pyridyl}(methyl)amino]butyric acid,
1-{3-chloro-5-[(4-(4-chlorothiophen-2-yl)-5-{[(3S)-3-
methylpyrrolidin-1-yl)methyl}thiazol-2-yl)carbamoyl]-2-
pyridyl)piperidine-4-carboxylic acid,
10 1-{3-chloro-5-[(4-(4-chlorothiophen-2-yl)-5-{[(2S)-2-
methoxypropyl](methyl)amino]methyl}thiazol-2-yl)carbamoyl]-
2-pyridyl)piperidine-4-carboxylic acid,
N-[5-{[butyl(methyl)amino]methyl}-4-(4-chlorothiophen-
2-yl)thiazol-2-yl]-5-chloro-6-[(3-
15 hydroxypropyl)amino]nicotinamide,
N-[5-{[butyl(methyl)amino]methyl}-4-(4-chlorothiophen-
2-yl)thiazol-2-yl]-5-chloro-6-(3-oxopiperazin-1-
yl)nicotinamide or
N-[5-{[butyl(methyl)amino]methyl}-4-(4-chlorothiophen-
20 2-yl)thiazol-2-yl]-5-chloro-6-[4-
(hydroxymethyl)piperidino]nicotinamide, or
a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising the
25 compound according to any of claims 6 to 11 as an active
ingredient.

13. The pharmaceutical composition according to
claim 12, which is a platelet increasing agent.

5 14. The pharmaceutical composition according to
claim 12, which is a thrombocytopenia treating agent.

15. The pharmaceutical composition according to
claim 12, which is a c-Mpl ligand.